Global Medical Affairs Lead, Early Prostate Cancer
Johnson & Johnson
Dr. Peter Francis joined Janssen Oncology in the US in October 2015 as a Medical Director focusing on prostate cancer, specifically abiraterone acetate with prednisone, apalutamide and niraparib. He participated in multiple work streams in support of the prostate cancer franchise including key opinion leader engagement, advisory boards, promotional material review, business development, Real World evidence gathering as well as Sales Specialist and MSL training. He has also helped to develop several new clinical study concepts to fill in knowledge gaps in the management of prostate cancer.
He obtained his medical degree at the New York University School of Medicine in 1985 and finished a three-year internship and residency in Internal Medicine at the Boston Medical Center (combination of Boston University and Boston City Hospitals). He then spent 4 and ½ years at the National Cancer Institute, specializing in the preclinical development of antifungal drugs in a novel animal model system that is still generating data today.
Peter draws on over 22 years of experience as a practicing hematologist-oncologist in Northern Virginia where he cared for patients with an extensive array of solid tumors and malignant and benign hematologic disorders, placing dozens of patients on clinical trials sponsored by the NCI as well as industry partners.
In 2007, Peter was in the graduating class of the George Washington University School of Business, completing a 2-year MBA program in Health Care with special interests in Health Policy and Pharmacoeconomics.
He has been on the Global Medical Affairs team as the GMAL for niraparib and early prostate cancer assets. He looks forward to daily challenges in advancing niraparib in the management of prostate cancer and introducing novel pipeline agents in solid tumors to internal and external stakeholders.